<SEC-DOCUMENT>0001193125-13-416194.txt : 20131029
<SEC-HEADER>0001193125-13-416194.hdr.sgml : 20131029
<ACCEPTANCE-DATETIME>20131029172359
ACCESSION NUMBER:		0001193125-13-416194
CONFORMED SUBMISSION TYPE:	424B4
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20131029
DATE AS OF CHANGE:		20131029

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-187508
		FILM NUMBER:		131177192

	BUSINESS ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B4
<SEQUENCE>1
<FILENAME>d619135d424b4.htm
<DESCRIPTION>424(B)(4)
<TEXT>
<HTML><HEAD>
<TITLE>424(b)(4)</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP><B>Prospects Supplement No. 8</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><B>Filed pursuant to Rule 424 (b)(4) </B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP><B>(to Prospectus dated May&nbsp;30, 2013)</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><B>Registration No. 333-187508 </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>125,000 Shares of Series A Convertible Preferred
Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>12,500,000 Shares of Common Stock Underlying the Preferred Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Warrants to Purchase up to 6,250,000 Shares of Common Stock and </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>6,250,000 Shares of Common Stock Underlying the Warrants </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g619135im01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCA biopharma, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement supplements the prospectus dated May&nbsp;30, 2013 (the &#147;Prospectus&#148;), as supplemented by that certain
Prospectus Supplement No.&nbsp;1 dated July&nbsp;17, 2013 (&#147;Supplement No.&nbsp;1&#148;), by that certain Prospectus Supplement No.&nbsp;2 dated July&nbsp;19, 2013 (&#147;Supplement No.&nbsp;2&#148;), by that certain Prospectus Supplement
No.&nbsp;3 dated July&nbsp;24, 2013 (&#147;Supplement No.&nbsp;3&#148;), by that certain Prospectus Supplement No.&nbsp;4 dated July&nbsp;30, 2013 (&#147;Supplement No.&nbsp;4&#148;), by that certain Prospectus Supplement No.&nbsp;5 dated
August&nbsp;6, 2013 (&#147;Supplement No.&nbsp;5&#148;), by that certain Prospectus Supplement No.&nbsp;6 dated September&nbsp;4, 2013 (&#147;Supplement No.&nbsp;6&#148;), and by that certain Prospectus Supplement No.&nbsp;7 dated September&nbsp;23,
2013 (&#147;Supplement No.&nbsp;7&#148; and together with Supplement No.&nbsp;1, Supplement No.&nbsp;2, Supplement No.&nbsp;3, Supplement No.&nbsp;4, Supplement No.&nbsp;5, and Supplement No.&nbsp;6, the &#147;Supplements&#148;), which form a part
of our Registration Statement on Form S-1 (Registration No.&nbsp;333-187508). This prospectus supplement is being filed to update and supplement the information in the Prospectus and the Supplements with the information contained in our current
report on Form 8-K, filed with the Securities and Exchange Commission (the &#147;Commission&#148;) on October&nbsp;29, 2013 (the &#147;Current Report&#148;). Accordingly, we have attached the Current Report to this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Prospectus, the Supplements and this prospectus supplement relate to the offer and sale of up to 125,000 shares of Series A Convertible
Preferred Stock (&#147;Preferred Stock&#148;) which are convertible into 12,500,000 shares of Common Stock, warrants to purchase up to 6,250,000 shares of our Common Stock and 6,250,000 shares of Common Stock underlying the warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement should be read in conjunction with the Prospectus and the Supplements. This prospectus supplement updates and
supplements the information in the Prospectus and the Supplements. If there is any inconsistency between the information in the Prospectus, the Supplements and this prospectus supplement, you should rely on the information in this prospectus
supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is traded on the Nasdaq Global Market under the trading symbol &#147;ABIO.&#148; On October&nbsp;29, 2013,
the last reported sale price of our common stock was $1.53 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Investing in our securities involves a high degree of risk. You
should review carefully the risks and uncertainties described under the heading &#147;Risk Factors&#148; beginning on page 5 of the Prospectus and beginning on page 22 of our quarterly report on Form 10-Q for the quarterly period ended June&nbsp;30,
2013 before you decide whether to invest in shares of our common stock. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any
state securities commission has approved or disapproved of these securities or determined if the Prospectus or this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus supplement is October&nbsp;29, 2013 </B></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g619135im01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g619135im01.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`1`"_`P$1``(1`0,1`?_$`*L````%!0$`````````
M``````8'"`D*``$"`P4$`0$!`0`"`P$!`````````````0('"`4&"0,$$```
M!0,#`@0#!@0%`P4````!`@,$!1$&!P`2""$3,4$B"5$4%6%Q@3(C%J%",PK!
M4F)R%Y$E&),D-#49$0`!`P,"!`,$"`8#```````!`!$"(0,$,05!$@8'46$B
M<9$R$X&A0E(4)`@)L<'1(S,5\9(T_]H`#`,!``(1`Q$`/P"=7E7*EL8@M9[=
MUVN3-XQH4A$4D2`J\D7RIA*A',4`,!UG;@?RA2G01$0UZ#W)[C=-=K>E,GJW
MJ>Z88&/%^6/QS/@`:+RFS;+N._[A#;=LB#D2-7T9-I37N'9)>2K@MKV%;S"'
M%<`8_65G[R24;"6@*/$F(@1LH!Z!3K77S2ZB_<&ZXRMSYNB=LVS_`$=PM:ED
M&Y\POH2THCZEV`V_LCMD<4?[B_DPS"-(\O*_DXJMC?G%GURL1,EGV"F4PT.*
MI9HIBE$:E4+54M2[#!Y#KQ^/^NWOG=OG&.S;'SU`/]ZI_P"Y%/YK=WL_TE&)
MD,K+#,#\&O'@KK\Y,]H;U!LRQS(E`Q@4VRQ2%3*(@)E3=\1((TJ'I\-8N?KP
M[YVID3V?81"W'UD_/%>#>OZM%8]G.D[A:&7EN8T^#7W+TVO[AUZM))E^_;(@
MEH=4P(O#6T[<)R*!AWF,JW1D%`2<@FD3<)1,01KT'7G^E/W#]WV_/A<[E8.'
M'9)$1,L2-R5P3)`H)29F=_H7\&]]EL&SA&]LU_(GD1U$^7E(J^@!?1DYC8=_
M0.1+;B;MMF1;OX271[S94G14!V_J-G"8&,"#ILH-#EJ;S'7TVZ6ZLVOK#I[%
MZHV&9O;1F6A<A)@&!`/+*I:0>JX"SL#*V[)EBY<#"<3QXH=>0>?A_'[M>T:L
M5_&K&':`FZ4`!$=P[0Z!\?`-5$2%Y<A<6V!E+&6&+KNR.A\D9@3F3X^MIP5R
M=>XC0"2:TL1NX114;-OEDE`V=TQ3*F`0*7H.@8A$=:2O=(!Z&(/@)3!U#U4K
M^--$7C?OB,4%W*JA4D4&[ATLLI42)(-D^\LL)2@)A3(D`B-/4'D`Z(D61_N4
M\$)!W(QR7*C$+>2B'+EG),).YD(E\V<LUSMG!#,I,C1R<B"Z1BG,4HE`2U$:
M:<AU=%YIWW-N!%O+E;R/*_#G>`P`HV87*C,.2%,4!*HLG%%=F;DZUJ8*"7J`
MZ:(CBQ+RQXYY[46)A?-V,<E*(;!596K=L3(RI*E$QB_2DW(R`F+0*@*84KUI
MHA/*S\4H5)<JHF`M:DJ!BB`E,`UZ5`?`#!HBP67,02E3`IE1"H)F$`*(_P"4
MQP$=IJ5V@(>H?/1$D;.7/3B3QP>$BLQ9XL.UK@.8Y4K19R![FO->@@`%+:EM
M(2TZFKU\!0'\=&?BR),P>]%P&1<"G.9(OFS6'44[AO7"V6K9MI=.@F!5*:E+
M/0:E3%.AMQJ%#S\=5N7S5#<4K#!?-KBSR8>.(S`^;K(R;+M6'U5Q#6^]5"61
MBP-ZGQX]X@W=E;AX`<2`03`(`-?"%&.O!*E15,H0IS%[8C4=HF#_`#&"GF-0
M*`#^.HX46"RYTQ+M*4Y3#VP'=015-T(3H4:`(^=*!JHB4Q=R'Q7F6X\H6ICB
M[8^YIO#5W(V-D=FU(X(%M7.JR1?IQBRZB1$W9E6JHF`Z=2`<@E\0T1'I\/O'
MR^_^&B*^B)H_W$961>9!QU:X"Y4C$+<>3!FJ2HE1,X=R*S)5T=(/ZBC9-L3:
M'B.X:>&OE)^X+U!G2ZMVOH^5V1VJ_M?SC99XRN"_<B)$\*!O<NR/93;\..SY
M6^3@#FVLJ,(G5HF`)I[?YI/&.+#1FUVD:)TXF47.*+!?LG,V>`;U@D[.IU0%
M80H0P^`CKJ!T'V[GUE'%PLS&C8W*%X#')+6R15I2T8LP?BO=^I=_RX-G"1G8
M@7G'B!XQ]GAX)9%HX;[R5NOY1DDP^BS`0]Q$=@C7:0HJMW20F$#*IG*(%/MJ
M`T*.N]G2_8?9YYF+=OV[.-:Q<@6\OYLC:,KER`G$VG^*$1Z2=":\2N)=TZNE
M+*N;?B/=,X?,C(:,?^&KHN=<6%735F^2:L$3R5PRSP&*A0$B3>'9[E1664J*
M94%>E-W4`Z!KQW4787(ELNZ&Y8Y<Z[E2_"BAY[4=)2.D8GA)?OM75MNY=A>N
M/"%F#R<UE)V8?T"1SD6QT(QPX9L.Q(N$$S=YXFB<K,S@0Z(MJ?U12$H@)S=!
MUT:ZQZ6Q]KF,;'QQEV;$C\\`&0C<(+%_(@Z:#VKEWI[?[DYVYY,?R]ZY$!]6
M);W>:6;[>#YR2!R-!'4<F:Q\XR<((J`'8267;F!PDV$.J?K"H@'37T%_;RWC
M<\_I3>MOS<BY*QA95N$;,AZ8<XE+T@Z!@-%P[WNQK-G>+%ZU$"-WG9O(IS),
M_P"F`CT$H=0^`@'Y1$?$VOHY'U5.JX07F<!O07,=<H(BF90!.4I$TDR%$3]T
MXC02@'C7IK88T.BB@N^Y/R,R?</,*S.>=KB]/A7&.85,28*DD#KF;3;[##U,
M;^<I'`.T1O<3IT\3(?P6!*E1`-0!A1%->P]DR&R_BW'65;=6(ZALB6?`W2R.
MBH4Y$BRK!!VNB40KN%HN90AO@8E-4T=E&*,P_;-4IB`J4Q1(8I@`2;#`("!@
M$!`0,`T$/AHJHY?]PQA+$[3A]!92;8]LN*ONW,QV.QB[KBX)A'R2<5-NW#28
MCG"K1%(\@WE451`R:M2@?U>(:A$>4D$NA\D9GL18*PROP$L2_76+K$>7I=MS
MY"+<5RR5N1<C,RH-;JE&39%V\=MUC*)-6B8)D*`@4I0H&M2]$8R-7#H$@OW^
M.+F-<"N,$<K,$0S/#>37UZ_L^:F,>TM$T@Y;-'4W!3YTHP[=L::CG4>"91V4
M63/M/4NLDN/2I*(DPEP3ZOMB\AKQY/<'L)9AR$N+N^I>'?PMRRB``F,[+6I)
M.8)>9.D0"D36DS,@4.4H4`YAT#M75:-4T_[N_N5Y;:Y5A^`W#>0.PRM>DE!V
MUD*]H=9,99H_NXZ36.LFU'(%,9C)D06,N_=%,"C=N`E"@GU5'&GVDXEP%]KC
M"'#JT8J9G;;C<J\C)1DV?Y`S3>C7]P3[V:>%,H]90*\J9V:*C(_O=HH)[3'V
M;AZZ,$`('JU3DEP61:-S0[V#N6T[:FX1ZW692$5*P4<_8.V3D#(JH':K-SE,
M1P0VT0^&LL7\E`_'1,FXP]O.)X:^Z/:&9\`68M&8)SICB^+?O"WX1HH6&QK>
M#0!D43(K5$&MNSJJX_+H]"I*`(%Z:W*,&#._M6C(G5/O-3"!0((`!@"HE`!`
M*]:`4?`Q`"GJ\]9$0-%$F#F;R*A.+7'?)69YHW?5MV$5C;8B4C"#J<O6=_[;
M;,,U3$!!5P[D'!/32M`'0NU-4IQ+!16O:5RIE3B%[F-Y<?,[J'CYOD:F9Q?;
M)RO5FED6X&),AVG*$$U15=N6DHK'@`#M\OY:!H,1YJ^@:2!*FD%7*=4R92B.
MP?4?<&THB'Y?]WV:R5%Z=5$TSSL:KN<TV&5N"8G)9('H<X(F$2SKX2[%3!3R
M$!`!\]?(_P#7W9R;_=[8X8QC$_Z.I)%?S5RC,[>;KLGV<N_)Z6SIQ<R_%1/+
MPI&/]?J0HPM"%=HLFTP-KR#!<Z*96[V7;-9(AA$5"HMW2*(N`6*8/2035-KV
M[L%T[M=^WCXN[W\"&)Z1(&?J/-$R<5YA(29C4<%X'K//NRE*%J-Z$A,N6>'*
M_$:O].BUQ=]C>>1IT)AVH,'`RB\1&1I':A8]"-AW)XX3N4SF*95V4[0XF,8=
MQZA\->-R.Y&]]>=PMS'5WY/HS:<^-KY8'*\;9Y(EG$JQCS..!J]%^9V>UMW3
M\,JS'FNW')ERD4D`Y!+^X4'@E.J2-M%<1L%'.EUF-PH*MW46942BL)$]Y=BY
MRCV$5@Z&$!*%/.NNV^1NG2^7N./L6W7Y9.S9.-7&A,&X+%)1(D\I`2DSOH'J
MO0IX>1+&E=D.0PEZ"Q/TD.*_4DC9EB%B!((,$[9AHQ`>TV8Q4@U6='01`P;7
M3I43KN%MU?20P?PUTR[Z8659OG_01VS"VB(E$VX2$[A)!`,B#4M\1.A:BY3Z
M3SIP%JY>_$7KXBWK#!W'PL!1"_@"D<BF4RG4*8@/XVFS8?H0BAJG.F`)]VOV
M5IXZY"_;Q$C@]73O3$[OX_'%&:D)A_;XKQ_>OU3V^0^Y(E]7DG)R!1+^7J`G
MZA7H8.@F"H`/CU\-?2<``47!";>]T?DJ?C7Q&OV0@G"2>2LG*-\,8NCA=-V2
MCR[[_,:#;/T%53H_+MX9%V=T=8Q@*0$NN@<(3$5.B;QYB</\-)>T1&<;;0R5
MC60R#Q_M"+R'&.6EZ6PZ>35^0K5>1ODQ"DE3+J*SB[UVH:E3JF`H=1'K2@+>
MJ7P+I_V\W*$F4>+T[@:9>&/<V!YIN$(54XF<.+"N3:Z8F1(H8PD:Q\D4Z1P_
MD[H=>M-#561^ZI#R1JE_F$0&@F,`%$:>?@'0-%$P[_<0B<W`)$`$$S#F[&?;
M&H`4#!)K"0QA4#:/4/NIK!'I(EQ*"FB2[[5_N+\<^)OM_8\MK,R.2K?0@[DO
MA:0N^-QG<LS82:DQ=LFZ8I)W:P;#%&4536`HE[A>VI4@FKTUO@!J`$0-Y`O<
M@^_G?=JV7QK;$QMQ+P1=+A:^LKWXJW1NFXKKD61T4@M^QT%7#]!`D4LL#1=R
M($.J-1Z`)=6,@3S$54):!/$*1=@_#EE\7,%6MB+&30&=G8OM%RQAR.1(H\D5
MV#-P^>24B8B2?<>R#TPJK"`%J8XTU9$&HU6J-350V?:@:?\`.WN\*WS?*J,C
M*1]V9FR0(.$U5-T\U=R47"J-555%1*+)`0V@-3)[.@AK,?A]6J@)9F"G4()]
M1.)4AW%+4Y1W5&G42B8!-0?M$=%`&+U6Y4@B'I`1Z@(A4`"A1K3R&GW:*^2T
M?*B!!3W42$!*!``!VD\D]IAV"0H>'0=0!D6M4I$0`AQ4V%$IBT$P@7T]LI0(
M0@F`H`-```'KY:JB8ZYNW;:')GG]QEX83]P6_#XVPF5KRKSD[EYV-BF3V0@W
M'9L&RGWSKA!(ZKEWM<G(.X0)U$``-'(K%"'%`#4)K+W[+=A[$Y*\?^9^';OM
M66E'/TR$F5;.N>(DY)C=F.G);CM1ZY0A7:CE)N^8*.&HKGZ&])*T"FDF#2&J
M-'[("E.<8<S6]R&P7BC-%L.6[N,R%9<'/JJ)*`J#:579H$EF*AB[`*Z:/2G(
M8!+NW`/71@=54H?1$T7S[7*WS-8!UAV-PL@X*+;NJ9OK;P2[2%J?<8"T`:4U
M\A?W!XY%ONOL>7"<!CQV,B0-)?\`IN&AU^A=D^R]LRV#*8?%EQC[/0"O+ABZ
MBLG#9.)B(WYM,Q5OKEQG(X90Q#CZEC$"B93D)42B(B8IJ:\+V4[A;`,NQA[5
MCX=G?V_MY62";480#3,@:$D.W@=%KK;:)7+$LG(N7.>3\D(4YB^A\O-&#=&*
M(J\9TU]XTO-K$/IR;^G.XV91.TB9J;3024<R,49`AC$2<'/54FT2B8U:UURW
MU7VEVWKWJ^/=7M]OUG$R+DAAW[.0XQ<Z^(Q)NVH,QY"6,N(("\'M/5&1L>(-
MDZFQYWL*-HR!AZC:=F$G;7A["AC:<$SL+Y>8NV[T)J:>*/V45),B]VW+>EFA
MNVH@_P"\)7`F7KM`-NW;UU[GT/TMMW;G-N=0[[OMB_U7G2G9M9<1RX.#*U\4
M+O/RN)Z1CIX+PN^Y\=\R18VRP;./;M@L[&Y$Z&G%ZI-V7+JCG;ETUE(V+A)`
MA%!4>PX'!N]<@7NI.$$E*D,*Y#F$3IB)0\-=4N\'55C<<R5O<,2SCY(O7("]
M8!C;RA5[T8F@!9Z$@NN1.DMDW"SCVLF-TW`"'C)F@/Z^".7V^%.[_P`K;!)M
M/)1AB^D2"<IDE!`QZT`#','77/O[<]N-K;^K1$B499]F0+N0T9`/[05ZGWMM
M_*S<3G))E`M2FB<G%<X%(!2IB8P"3MB8=X@`B%2!_,(T^[[::^FD`PJN"6H_
M%,"Y7A+:]QSW383"4TR0NKCEP;M-Y<>28Y10ZL3<F8+I)\I$0+LR2G973BVZ
MM5"E,"A>H!30R;044#'BG%O_`,UN"NY03<;K`(=P0Z*P'"8$**E[2NVLB8AC
MBG4>O01U8EPL\M:EQX*+SQ>N%S[:/O+W9B5^V<P^+KYOIWC,B"INPU-9.0'`
M.;%FRIG$@+MH2;[:(*@`@"0"`]=70+4::U4VQ)97J6A3@4P`<V\!`"]LIPV=
M?4`@;SZTU`_%$Q)_<0[?_`)`%!*-<Y8O-ZA*4G_VI_0/6@5KT#Q'7YW"3;,A
M0A0%UWO9AQ[9^6?:BL+'M]P$9<5GW9(Y5A)N(DF[5RW<L7MW3;<RB8+$5*#E
M"H*(J!0Z9R@)?`!UNV2;<3+4Q"J8EA)G*'L8^XG)0+A29G\$W>9+Z@DX!XHP
MO/#DN]$&\^W`NU%2[<;NU0*<P!N,FGM'H>NEL$D@EF0UB8'0E39++NRS\I69
M#7E9TK'7#95ZP*,G#S,8X(Y:R<1+-"]MPDNF)TZF04H8!$*"&JU7="*TT4(F
MUDY'VO?>(CU<AI&A+`=9+EO^\*(G*S=XNRXY<D:W`V,4`37:1<H[(DX$!'LB
M6HT"ND@Y<40D\&93H6<FU>M47L>Y;O8]RV1?-';8X';N&;@`.W6;*DJDL@H0
M0$IBB("&JGM7O54$I-X``^`D#=M,8!"IJ5Z"(%J-/LT1)PY%<I,=\9K>M">O
M[ZB\<7Y?4%CRSK?M]J,A.7!<-PN"(-4F30#%,*+5,_=7,/\`3)U'5`'$LC$Z
M(S\DY$@\6V#>>2[N7)'6S8MK3%U33UPN1(B#2'8JR#A(XC0@*&!+ME"M14&@
M:CAV"4/M"8D]M?B=C+F98F8N;G+#&49?%V<G\JS\_8Z-QF?$5MO%$([&+M!E
M'%1<MEVS=V@EW1+N$#`("`4'0%JA.8#7BCMY\^UMQPN7B-FAG@["ELV;EB!M
M9Q=MD2T&5Z655D;6$DHLP05=NW*0ED8]JHC3;4=]//6!$@^2R.4%WU21?[<G
MDRG/8KRCQ9N%V=*=QC-*WS9T8Z,(+IVA/+D;S#(NX1$ZD3/E.!DR!4A1K36W
M\-5IX\-5)I(MN2,K0`H4QJ5J/3=X@'4*T\/'4KQ4JF_><^%)V]6$'D>T6QWT
MU:3)>.EX](G=<+V^Z6.N=RR2J'=<,%1.<2^)@'I370K];/9'=.N=EL]?=*8D
M\_JC;['R#8B:RLF4I@@>(E*3T+KE_M5UC#8,T[;E5PKMT39VJ`VOG3W)K:#O
M96)(FP.X5;(K'4([;JE,T7*F0XB955-02KI*JF+7::M!U\G<;J#>>G+4-OOQ
M_!;A;GRWK-QQR2?246',"/-=D\S:L'=<>.5BRA*V"^H>M6!X)1$)G-..DK?(
MF^26;P2B)FXG.F4IA5,H98Q@.:@++B<`W=:`0-<WXW>ZWM^Z;/&&39_#X,6$
M``+<"2)&0B"/67(YI.U%Z/F]"QOV+X(!E?!%3S'R!(;3^:Y<IF/OMIAB9\EV
M7\H,J#<BA#)I.R&-N!)90P@(J)F'<7SU_'U!WGL]38>7L5_*$]N-\W(QD1(2
MN<W-S$.*"+AAQ8K>#T59LFU.5N,+D8B,F^(Q'!WI6OU(BI>[W\]V$$!-)F%0
MK..;-TE'LFJHH!S(L444A.H!2")@(`4"AA$?`-<,Y&[[]UADB>S#)W3+M3^3
M;@'_`+8DPY8BH$`!4M2E5[E8Q\/:;4K]P"&+`.0X#MX^)*=WX8XCFL96`M*7
M*B9I<%Z/$YAVP,4RBC&/%,`8,E]PT(\()JCT#;YZ^SGZ0^RM_M)T3>W+.D#N
M>]?+O7(,082$?@+DU#ES3V+JUW*ZGL]2;ORXA_)VG`&K?2O/RJR-S`MQN%L\
M5<"P60KAG+>7!GD*\KU:P%LV;+JE.W3,^B1;*O)-1I7O`4AB%,8``:A77<")
M!@>!7&W*&U34OMW\?/<5X/7?EE?*>"K*S0;D1D)G?5\Y&MO)#9G/PLJ]<'2E
M7#QL[8G!Y&,VS@QTVZ0$$.V4`&NH9`#E:IXHT0-*J0/=DM/0]N3LG;T(I=,_
M'Q+M[$6XD_(P&<DFZ1S(1:3QP"R3`[E0``%#@8I:U$.FI$<H9%%<YZ<`/<6Y
M^YWA,[Q>!,<X+7M:T6-MQ[=_DU!Y=C]S'282T=,/)&.9I)?.,7)0*GL`NTM:
MUU355AXIX_AS?/N*P;*V,5<N,$VF_7AH)TS>9VLJ_P!BY8S9XMJ0L8$Q:RC!
M-?ZC(``)&4(H4HF#<(#75F1+X:*)"/N,X=]RWW"+#C\'6SQRL'#V-HB]4+LE
M9N[,I-I*=NA:WG#I*`;LD6#%)*,9J#VW)@$#'"NVO36#(1-0X4$FJR&?M[6#
M[DG!K&-O<;[YXUV'E/&L?=+QY$WO9^46[";@(ZZI=22F4Y.,>QZR,HE%N7!S
MI&)L,)/3Y:U0U%`M!CK1*V]TC@*RYT<?W,)"(-F.;\>**W+A^Y'12(UDC(J$
ME+1D%BB4@P<^U.**F^I4U=BE!VAJQ(B&XE#Y)O[V_P#&'N]<&<9ML=3^$\8Y
MCQ`T%PXMNPR9+;Q=]6(JZ6.NYCX67.R/'N89PN?>"*I#=KJ!1`*`&`#$-JH/
M-.0<R>`.+_<2PW;C?,5J'QME^,@#N+7NN-73?S^.IF4;I*/X9T^;B@C/1!G!
M`*HF(=L0"I:#UU0:L5:<2D0\:(;W7>`48WQ-?F,(;FKQ_M_<WL^XK*NY"&RG
M:\*@H<K5E\C-`L24:((T$B)C"<A?2!@#IJH6X%TL>3YR\BIE@Z;XS]O3/4E=
MJC50\>WOJ9MNSK=!8``QOG9D%7JJ904*%0*4!.&LDMP42$[$X8^Y!R(YRX2Y
M5<U%,7P^+L42<I-6IAVV+F7D$K*.JU.2.2;,44DV\C,BL)06=JB<X@'B`:`B
M6HT5KP*'ON*6'[GG-.P;MX^8@PO8V'\3S$FNQNJZKGR0BI=&08%NLH!&#5HR
M9]J'B)`P%5.!A,J(!MKU'6R0S`5*S$U((:FJ6GP*6Y167CNT,"YUX[0.+(W%
MF/XJW8N_[/OIA/0%T+PY$V**3*%!FD^CW#E!/N',HJ<HF'PTHJ0-4H'D-?><
M;!@HA;"^"T\ZR\TK(1DG$.KM96>R@FP,%`:.)!9VW<E=L':P[%2$*!_56O34
M)#4!=&CX*+UQ_P#;$]V7C'R%<\IL1VGA"(N5[.W-*O<?N+V54AI2U;IDSR,E
M83X>SM(S(13:BJ6AR*!O*(:I8-Q4](-`I+>+,M<J+HQEE69O_C#&8ZR?:UDN
M)"P;1'(C"=@,CWJE"3Z[6WB2[9DB>"BEII@S;BNJ0PE1>;J"*8U4X+5$L19#
MN&W>FFP2B`]:AZJE$!*8HE,`]=?C*,QS&V1S2$17@Q)/\?!1GJ"1('4(J9S"
M.+;F>J2,Y8EM/GR@^MR,8DFLH7X*G1!+N>/B(`(:XRWKLOVHW_-GN.][%@Y6
M=<),[DX>J1\V7FL;J/?L*'R<7*N"SX$E<G_QPPH``8,;VT!_2(C\F8X;@V^`
M&5Z!Z=>)C^GSL:#S'I;:3(AO\7NXK^L=9=5`@C,N!O-8CQVPI6@XXMX0W[@*
M#0PEW"/4X`*H@!J=-2/Z?.QT>5NEMH<5_P`7'WI+K+JJ4N>6;=)9=VW<-8SM
M9^G)6Y95O1,@D(F!RC&)&<E])2;TE%!,"2@4Z"`5U['L/:CMMTSG1SNF]EP,
M*\`7^7:`=_%W7\>7U'U#G6OD9>7=E9=V?P^E&65(3;A4VE`HB(4`2_F#8(F$
M#!N$2#^`^&N0+=BU;'+"($>8D`>?DO#&H+ZE<F<EP@HN3ECMEWH1;)5\9LW`
MH+JMVJ`+N.V"QR)&$`*(TK77[`'F#:*"(!>KHML*Y8#,-I*7FSM^0@(9S,O&
M$2$DLFL]D&[)7LK/3IHB8J*0K!M('6NH35@"I4^]"C)5_P`7C"T9:\G\1,S3
M2*[!G$9;D:I)S+D%S@W*#1HCZUC$I4P!X%ZC36F*TA/!RK>5B8V7135:H2S)
MG((MG93)ND4GJ)%T4G"1Q`4'"?<VF+XE,&HH7BNH<Z!B@!S)B`FI2H#4Y*AM
M]5:F)3Q#KYTT5%5H^8VB`+'1*!EMB:BAR)%4`2;B=L:GWJA0:!4!$`\-9)C+
MT@('U6\PE,0Y4S%K3<;U`:FXP5,/J`0W!]NJ&T\%`(FI"(B%S4A.YMN/#+:V
M)I!Y;$$E,SEQN5VB<8DV<B0L:1HBDHNJJ#WN#ZC]L:D\!#6C;BW,J]:(]`41
M`3$$U3`!U-XT$GK'UC4!`E"UZ`8:@&H`!IHHY68*H$`![A"@!2A6H4`!$2E\
MZT.(=`KY=-3[7DA#U*S_`$]VVH;R`!@*4?R`-0J)0$IJ=.HC35=`PH%<5"@(
M;CE+N](`(@(F$0$0`H`-1,8I>@!_T'40%UK.9OZQ,=,NT?6:I2F*(T]1S5*8
MHB/C7QU4KP5RG3.&XIB&`M0"A@H&X`-U]6TH"`_E&HZ$&G@G\5;NHB:F]$:%
M,)"[D^NT:','01I7Q$/+1*\5<5&Y*?J%*`"`5J(T[G0`K4>@CY]0KHJLBB0]
M#$,!ZC0!W"`F`@C]G4"_$/'4%'=0AR"MI2;2B'F-?5XB-:]1_$?#RU55GHBK
M1%6B*J>?GHBJGGY^%=$6E18J8&$=QMM!$"%W&H(TJ`?`//1$DCF'D!:T<3.[
M=AB.'%T9/?H67;[!F0RDJL>5$B<DJS3J*FY-J(@`TH035'H&K%W<<$=C35`S
M$$KD:R<EV=A!Z2W@LR,Q2277AXEJ8\Q9QVH$09C/2JE2N'LL[4$QQZ$`X=`\
M].:9EP9UIY'5D*LHY0R;&94QAC2R$H)!Q<T\#R4(_2+*.GEELDN[-RZZ0`/T
MIJ18_:0.(`*AQJ'@.M2D10K"&&;LNR%D25E6'9L6UF<A9+E?HUL-G)!^F1#)
M.II6YY4$1`5&$*D`&%.E3F"@#K"T!]YES\09(N>8R=E[$MR2+2YG6-2VVLG=
M+9BG&"X_<$:FZ<1CY!J!6X/&*HB"9@`#"E2OCIHI\(#HA\CN+ZRKR0<6[`3;
M&T8_CS;#Z]EI5(1E&DA.S+8S:*;R[,U6I72+4JIQ3,%2D`3!K1$(5MUDRHN2
M+P:I2BN..59;*V%+=R9=;5A%R;E&7-,*,B&)&J_05UV:TDQ*Y$WRS9PDS$1`
M:E"HTUEW#\5&(H=4B_']XY.>63R-Y%VNK$P(25P34TWN"<CPE`E8"SD19Q=L
MP397T@Q=$0W"XJ)!4/0H5T=OCT"C@EAJEYP>23,,0VQD?(A6UNK/;8B9.:9(
M"``E)2*)5$H]@W,(**/':ZA4TD@ZB;H'AJN)5CHK_%$1>65,O/;LQ39D`6!M
M*X,D32DD[@U6@RUP6M8$04KE].29S[T&KN0;'!`I#%_2.J-.H#JM)FIRJEM$
M*>5.7+SP[8A9VT48XKMX]C6#)Z]2^?5?RCUXF@$.TC`_*\=)&$>]U*6OV:R/
M32/%0"-2=4-<>$SM(3Q)J^G5H,['DK78JL[9CFJX7!$38E(=8KU\<=KA-5,]
M3E#H0U`^.I*?WE2242\[F_*P<@$\90#2VDX.,M*1G;E*L`+)6HB!%3,):XI4
MG0CDJ*6\&8"7<`TU5$3<7R5SU+8J4N=LYM[ZM*Y/_9^/Y=2"$BV0D59+Y0C>
M*BB__"8,6X**'>B`@8M/@.M$CE`1."7/>D=85HFN>\G16(MF3,C])FF"BSN:
M<ID*2,BDC?J.)%T\$2)D3^\>FI&IIJH4FN8RIF"5RIBK&T($%;3ZYP=W;><.
MDP&7E+1L!F4#M32<BH)D&\E-KBFGMH`D,H(>6LD%Q[54ME-`>X4PC0"`!4S$
MJ41(00':8`](D/XCJHO;HBK1%6B*M$5:(J_CHBTG*(=2E+U$*]*CT^`")0ZC
MTU#I]*,Z2KE[$V0+JRKC+)EGO[45-9#69:!#7>#P[)FYDZ(_N*.(R*(KOT$2
M4*0PD"AO$-:!9_8C\H9&?CO&3*Q#3LFZ?FN2[[N<).[MNA^`?-OU"`8J+%J@
M`F!I$LR*"5%`IA+0:B`CK)T1%?;F#KO2SA?&6+FNEBHQF@C(^V8^);JEDV-N
M1:0"A#.7C@#%:LUW!CJKE1(`*'-3H`:D9&(85!4,@NQDO%EURV2K-RS8+B!+
M=5J0$]:_TVXR.4H@6=PI`4LL@NU355!Y'*%KV=M%2C3<75)`U2J]>.,>16`K
M,O2XK@G%[DN.85FL@9'O!ZW3;GF)1)%5=0B9$P$&L<R21!%J@43;2E\JZI]3
MMQ5C4L4EO"&.LM9!L*^;H+*0\%&\E)Z1N.X+F53<%O.'M!4R\3'1$6Q,D#50
MRL*8_9<'4*9N*HCM-TI!HR&Y*0:0Y2*!*QN7%BC?"4CA_%KR/M0IK:"UH%XZ
M34<H1\<KVT)!=11(Q5%7CMJ90PF$!$5#UTTU4X.=4`B8&N-Y'P.)I24MQC@>
MUVEI'CH*':/&]T7"\MTZ+IY'SK@54V985]*IE64[91,H`;3=!$=;)C(.-5IH
MLXU0HS_BB[\AQV/D+&D8".6L^](VY'#*XF[AU"R#..*)44%6K82%7^1,83HI
MG]._X>.L:4`HH@+8G'N]X'--W98N._$9L)Q"*29+MV9DYT[1B<%7,$4S@YFL
M?!K.!'])(.Z8I0]?CH\M`/2J61D9%Q`[R7D3'$]-/FIK'QZN[G#6H5-05IFZ
ME!`L:[<',<B!63%,`,!:;M]1T<:*(]'*+H6C@J2B!GG:<?+*KD$$".#E$4.Z
MF4?6F540$>M1*%*:,-4=DBLW&*\5<<WU;PWS&DR%EJ[OK&2[V29*@NYMH[SN
M*6Y%"FLFLW138%[)-WI`!'IJF9A_C'-XH_UKM/\`CC.+94Q[,0-PQ5O8RQG:
M/T&UX5DT45EHR45`J+J4:IJ@:+^;=H!M%P<ASI[C4"H@.H)"5?M>"(:YLQ5?
M-^26*Y"SIZ#9A8-T(3TBSNAJXDF$H5%'LE='0;'0%U(-!$3)`?:0%.NG.8GT
MU*(&XEX_WI9.4K^ONY;X).GNV61=(.DFJQYEY%();F\9,.G2HHL(QH[.8P-F
MY>H@GUH4:ZYWCZ@R)9``/3QKY_#RZ`'CM^'PU$6>B*M$5:(JT15HBK1%6B+4
M/:W$KLWT'96E=OGM^S1%EZ/]-:A7PK6O3^.GM16_2J/Y:TZ_=0?\-0,U-%D<
MKTU5?IT#\M-Q:?[J!M_&FA;BM(O\G?\`&W[0E_\`E/Z-^S/DU/K7UW?]*^2I
M^K\YLZ=BGYJ]*:H\E0[TU76LW]F_M:W_`-D?2_VG](8_MSZ13Z;]%V?^P^1V
M]/E-GY*>6BDM?5JA3^CZ?Z?GMI2G^JE-#I50LU=%7Z/^CP-XTK2@;J5ZTI2N
MH&:FBOL5&[-"[ME*!MKX4ITI^&JBL/8HG7M[=Y.WX4WU]%*>=?#1%E^EO'\N
M^H5^-:A2OVUUD<KTU17-LZ;J?F"E?\_E^.M(K%[6X^W9NZ[Z4K]N[4#.6U4H
MK!V=I=NS9N]-*4W5\OMKJ#E>FJJL?L?S[/Z9O_3IZJ4\M6C^:+(.ULZ;=G2O
1^%?/0LU=$6S5'EHBK1%__]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
